ASSESSING THE RATIONALE OF FDC CONTAINING OFLOXACIN AND AZOLES: DISSOLUTION, PERMEATION AND ANTIMICROBIAL STUDIES by PAWAR, ATMARAM et al.
 
Original Article 
ASSESSING THE RATIONALE OF FDC CONTAINING OFLOXACIN AND AZOLES: DISSOLUTION, 
PERMEATION AND ANTIMICROBIAL STUDIES 
 
ATMARAM PAWAR1*, AKSHAY KAMBLE2, SWATI KORAKE1, VIVIDHA DHAPTE-PAWAR1 
1Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune 411038, Maharashtra, India, 
2Department of Drug Regulatory Affairs, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune 411038, 
Maharashtra, India 
Email: p_atmaram@rediffmail.com 
Received: 22 Aug 2019, Revised and Accepted: 18 Nov 2019 
ABSTRACT 
Objective: To study fixed-dose combinations (FDC) of antibacterial and antiprotozoal products (ofloxacin and azoles), prescribed for the treatment 
of diarrhea. 
Methods: Rationality of these FDC products was verified by assessing parameters such as drug content and release by assay and dissolution tests, 
respectively mentioned in the Indian Pharmacopoeia (IP). Amount of drug solubilized and permeated as per the Biopharmaceutics Classification 
System (BCS) was determined. Ex vivo permeation study was performed on the gut of goat using the everted gut sac technique. Antimicrobial 
efficacy in terms of minimum inhibitory concentration (MIC) was assessed using agar well diffusion method against Shigella boydii, the causative 
agent for diarrhea. Comparative studies were performed on an individual as well as combination doses of antibacterial and antiprotozoal products 
for the synergistic effects to assess the rationale of these FDC.  
Results: The BCS solubility of ciprofloxacin (CPX), norfloxacin (NFX) and tinidazole (TNZ) was high in acidic medium (pH 1-5) and decreased at pH 
above 5. The assay studies showed that the individual drug contents of FDC were within the IP limits. In vitro dissolution results for both, individual 
drugs and their combination illustrated 99 % drug release within 30 min in 0.01N HCl. Ex vivo permeation of TNZ was higher than CPX and NFX in 
individual drugs. No significant change in the permeation rate was observed for individual drugs and their FDC. CPX and NFX exhibited more 
antimicrobial activity in terms of inhibitory zones than their FDC with antiprotozoal TNZ, above 2.5 µg/ml MIC. The pharmaceutical, 
biopharmaceutical and antimicrobial evaluation study showed the similarity of FDC with the individual drugs. 
Conclusion: The study showed no significant data to justify the therapeutic advantage of FDC over individual drugs. 
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INTRODUCTION 
Fixed-Dose Combinations (FDC) comprised of two or more different 
drugs as a single formulation are explored for a plethora of diseases 
for synergistic effects and patient compliance [1, 2]. The rationality 
of FDC is defined by similar pharmacokinetics, yet the diverse 
mechanism of action; without supra-additive toxicity of the 
individual actives and formulation components [3]. As per the 
modified approval process for FDC in India (2013); the 
manufacturer of various FDC like analgesics, antacids, 
antihypertensive, antipsychotics and anti-diabetics have to obtain 
permission from Central Drug Standards Control Organization 
(CDSCO) based on the essential data supporting the rationality for 
FDC [4, 5]. 
Ciprofloxacin (CPX) and norfloxacin (NFX) are broad-spectrum 
quinolone antibiotics known to inhibit bacterial DNA replication by 
impeding the functions of bacterial DNA gyrase enzyme. They are 
mainly explored in the treatment of urinary tract infection, cystitis, 
prostatitis, respiratory tract skin and joint infections [6, 7]. 
Tinidazole (TNZ) is a nitroimidazole derivative used in the 
treatment of intestinal amoebiasis, giardiasis, trichomoniasis, active 
against anaerobic bacteria and protozoa [8, 9]. 
In the proposed study, we assessed the rationality of antibacterial 
and antiprotozoal FDC used in the treatment of diarrhea. In India, 
physicians prescribe FDC of ciprofloxacin and tinidazole (CPX+TNZ) 
as well as norfloxacin and tinidazole (NFX+TNZ) for diarrheal 
treatment [10]. However, these FDC are neither a part of WHO 
essential medicine list 2017 nor recommended in European and US 
countries [11, 12]. So, the aim of our study was to study the 
rationality in combining the selected ofloxacins and azoles for 
synergistic effects by comparing individual and combination 
products using parameters such as in vitro dissolution, ex vivo 
permeation, and antimicrobial study.  
MATERIALS AND METHODS 
Materials 
Ciprofloxacin hydrochloride and tinidazole were received as 
generous gift samples from BDH Industry Ltd, Kandivali (East), 
Mumbai. Norfloxacin was purchased from Shree chemicals, Pune. 
HPLC grade methanol, acetonitrile, water were purchased from 
Merck. All other chemicals and reagents used were of analytical 
grade. Marketed tablets of ciprofloxacin (CPX) 500 mg/250 mg of 2 
brands C1 and C2, respectively, norfloxacin (NFX) 400 mg of 2 
brands N1 and N2, respectively, tinidazole (TNZ) 600 mg/300 mg of 
brands T1 and T2, respectively, combination tablets of ciprofloxacin 
(CPX) 500 mg and tinidazole (TNZ) 600 mg of brands CT1 and CT2 
and combination tablets of norfloxacin (NFX) 400 mg and tinidazole 
(TNZ) 600 mg of brands NT1 and NT2, respectively were purchased 
from local retail pharmacy at Ratnagiri, India. 
Methods 
BCS solubility (as per WHO guidance) 
The BCS solubility of drugs was determined in the aqueous medium 
with pH in the range of 1.2-6.8. Results for the solubility were 
calculated on the basis of drug soluble in the volume of 250 ml at 37 
°C for 24 h. Highest unit dose of individual drugs, CPX (500 mg), NFX 
(400 mg), TNZ (600 mg) was weighed accurately and transferred in 
conical flask containing 250 ml of water and solutions of pH 1.2, 4.5 
and 6.8, kept for 24 h under continuous agitation using Brunswick 
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Scientific Excella Incubator Shaker at 37±1 °C to determine the drug 
solubility [13]. After 24 h, the quantity of solubilized drug per 250 
ml was determined using UV-Vis spectrophotometer by measuring 
the absorbance in triplicates. 
Drug content 
Assay of CPX 
Accurately 20 units of marketed CPX tablets were taken and average 
weight was calculated. Further the tablets were triturated and 
powder equivalent to 1.25 g CPX was weighed accurately, dissolved 
in small volume of 0.01N HCl and volume was made up with 0.01N 
HCl in 500 ml volumetric flask. Solution was filtered using Whatman 
filter paper no.41. From the above filtered solution, 10 ml of solution 
was diluted to 100 ml with 0.01N HCl. The solution was injected in 
to HPLC system [JASCO model-AS-4050] with the pre-set parameters 
of C18 (250 x 4.6 mm, 5µ) column, mobile phase (0.025M 
phosphoric acid: acetonitrile 87:13 v/v) adjusted to pH 4.0, flow rate 
of 1.5 ml/min, injection volume of 10 µg/ml. UV detector was used 
for absorbance measurement at λmax of 278 nm [8, 14, 15]. 
Assay of NFX 
Accurately 20 units of marketed tablets were taken and the average 
weight was calculated. Further, the tablets were triturated and 
powder equivalent to 50 mg NFX was weighed accurately and 
transferred to 100 ml volumetric flask. The sample was dissolved in 
40 ml mobile phase and volume was made up to mark with 0.1% v/v 
orthophosphoric acid solution. 10 ml of this solution was withdrawn 
and diluted with 25 ml of mobile phase The resulting solution was 
filtered using Whatman filter paper no. 41 and filtrate was injected 
into HPLC system [JASCO model-AS-4050] with pre-set parameters 
of C18 (250 x 4.6 mm, 5µ) column, mobile phase [0.1% v/v 
orthophosphoric acid: acetonitrile (85:15 v/v)] adjusted to pH 3.0, 
flow rate of 1.5 ml/min and 20 µg/ml injection volume. UV detector 
was used for absorbance measurement at 278 nm λmax [8, 14, 15]. 
Assay of TNZ 
Accurately 20 marketed tablets were taken and average weight was 
calculated. Further, the tablets were triturated. Powder equivalent to 
0.15 g TNZ was weighed accurately, dissolved in small volume of 
methanol and the volume was made up to mark with methanol in 100 
ml volumetric flask. Aliquot of 10 ml solution was withdrawn and 
diluted to 100 ml with methanol. Further, 10 ml of solution was 
withdrawn and diluted to 100 ml with methanol. The analysis of the 
solution was done using UV-Vis spectrophotometer (JASCO UV/Visible 
spectrophotometer) method at λmax of 310 nm [8, 14, 15]. 
Assay of combination (CPX+TNZ and NFX+TNZ) 
Accurately 20 units of marketed FDC tablets were taken and average 
weight was calculated. Further, the tablets were triturated and 
powder equivalent to (10 mg CPX and 12 mg TNZ) for CT1 and CT2 
tablets and (10 mg NFX and 15 mg TNZ) for NT1 and NT2 tablets 
was weighed accurately. The powder was transferred in 10 ml 
volumetric flask. The samples were dissolved in small volume of 
0.01N HCl and volume was adjusted up to 10 ml with 0.01N HCl. The 
solution was mixed, sonicated for 15 min and filtered through 
Whatman filter paper no. 41. From the above filtered solution, 1 ml 
of solution was diluted to 10 ml with 0.01N HCl. Absorbance of 
sample solution was measured using UV-Vis Spectrophotometer 
(JASCO UV/Visible spectrophotometer) at respective λmax of both 
the drugs. The concentration of CPX and TNZ in tablet formulation 
was determined using simultaneous equation method [8, 14, 15]. 
Dissolution  
As per Indian Pharmacopoeia (IP), dissolution test was performed 
using 6 units of the dosage form. The test was carried using Electrolab 
Dissolution test apparatus (TDT-06L); the dissolution profile of each 
dosage form was obtained using USP type II (paddle) apparatus with 
900 ml 0.01N HCl and phosphate buffer 6.8 dissolution media at 50 
rpm. Temperature was maintained at 37±0.5 °C for all samples. The 
samples were withdrawn at time intervals of 5, 10, 15, 20 and 30 min 
from 0.01 N HCl and 5, 10 15, 20, 30, 45 and 60 min from phosphate 
buffer 6.8, respectively followed by addition of an equivalent amount 
of media to maintain the sink conditions [15-17]. 
Ex vivo permeation study 
Bioavailability is defined as the rate and extent of drug reaching 
systemic circulation. Intestinal permeability is principal determinant 
of drug absorption, post oral administration of drug. Transport 
across the intestinal barrier is a prerequisite for clinical effect of 
most drugs. Intestinal permeability is used for classifying drugs in 
accordance with the Biopharmaceutical Classification System (BCS). 
This study was performed using everted gut sac technique [18]. The 
freshly cut gut of goat was collected from local slaughterhouse and 
kept in a mixture of Krebs-Ringer phosphate solution and isopropyl 
alcohol (70:30 v/v). The gut was washed with cold oxygenated 
saline solution (0.9 % w/v NaCl in water) and small portions of 10 
cm were incised. With the help of glass rod, gut sac was everted by 
sliding it over through opposite side so that the surface of gut was 
inside out. Sticky matter was cleaned using cold Ringer’s solution. 
One side of the gut sac was tied using thread. Phosphate buffer 
saline pH 7.4 was filled in the gut sac and tied on the other end. This 
sac was placed in the flask of dissolution apparatus, containing 900 
ml phosphate buffer saline pH 7.4 (37±1 °C), at 1-2 bubbles per 
second aeration rate. Tablets were placed in the dissolution 
apparatus at 50 rpm and sample was withdrawn at a single point of 
3 h from the dissolution flask and gut sac. Drug release and amount 
permeated was calculated using UV-VIS spectrophotometer [19-21].  
Microbial assay 
Shigella boydii NCIM 5709 (National Collection of Industrial 
Microorganisms (NCIM), CSIR-National Chemical Laboratory, Pune), one 
of the causative agents responsible for diarrhea was selected as test 
bacterial culture. The assay was evaluated following the agar well 
diffusion method using nutrient agar. 0.5 ml of test culture was spread 
with sterile swab on plates. Wells were prepared in the agar plate with 
8.0 mm cork borer. Different concentrations (2.5, 5, 10 and 20 g/ml) of 
the drugs viz. CPX, NFX, TNZ, combination of CPX+TNZ (in ratio 2:3), a 
combination of NFX+TNZ (in ratio 5:6) were prepared using acetate 
buffer 4.0 and evaluated for the determination of minimum inhibitory 
concentration (MIC) [22]. 
RESULTS AND DISCUSSION 
BCS solubility 
The results for solubility in water showed that ≥ 90% of CPX was 
soluble, whereas the solubility of NFX and TNZ was ≤ 50%, 
respectively. The results for solubility in 0.1N HCl and acetate buffer 
4.5 media showed that ≥85% of CPX, NFX and TNZ were soluble. The 
results for solubility in phosphate buffer 6.8 showed that ≤ 50% of 
CPX, NFX and ≤ 60% TNZ were soluble. The solubility for CPX in water 
was obtained ≥ 90% owing to the presence of salt [14]. CPX, NFX and 
TNZ demonstrated maximum solubility in 0.1N HCl and acetate buffer 
4.5 whereas, minimum solubility was shown in phosphate buffer 6.8 
as represented in table 1. As per the WHO and FDA guidance, the drug 
is considered highly soluble with the highest strength of drug soluble 
in 250 ml or less aqueous medium at 37 °C over a pH range of 1.2-6.8. 
According to BCS classification of drugs, CPX and NFX belongs to class 
IV and TNZ belongs to class II. CPX and NFX are zwitterionic 
compounds, which exhibit “U” shaped pH solubility profile; they have 
highest solubility at pH<5 and pH>10 with limited solubility in 
between pH 6-9. Considering this, CPX, NFX and TNZ solubility were 
high in acidic medium (pH 1-5) and decreased at pH above 5. From the 
solubility result of CPX, NFX and TNZ, it indicated that the absorption 
site can be in the upper part of the gastrointestinal tract and less 
amount of drug might be absorbed through the small intestine and 
colon [18]. 
Assay of CPX and NFX 
As per IP, the tablet should contain not less than 90% and not more than 
110% of stated amount of drug. The drug content for CPX and NFX was 
determined using the RP-HPLC method. The retention time (Rt) for CPX 
and NFX was obtained at 13.68 min and 8.72 min, respectively. The 
samples were run in triplicates and mean of peak areas was recorded. 
The % drug content was calculated using the peak area and content of 
CPX and NFX was found within the IP limits as depicted in table 2. 
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Assay of TNZ 
As per IP, the tablet should contain not less than 95% and not more 
than 105% of stated amount of TNZ. The drug content for TNZ was 
determined by UV spectrophotometer, in which the absorbance was 
measured at respective λmax. Drug content was calculated using the 
triplicate readings of absorbance. Percent drug content was found 
within the IP limits as depicted in table 2. 
 
Table 1: BCS solubility of CPX, NFX and TNZ 
Medium Solubility (mg/250 ml)±SD 
CPX (500 mg) NFX (400 mg) TNZ (600 mg) 
Water 480.19±0.22 165.39±0.34 211.93±0.16 
0.1N HCl 489.94±0.53 389.22±0.40 487.92±0.38 
Acetate buffer 4.5 487.79±0.58 380.05±0.68 487.62±0.47 
Phosphate buffer 6.8 231.51±0.74 181.17±0.82 253.01±0.54 
CPX-ciprofloxacin, NFX-norfloxacin and TNZ-tinidazole, All values are expressed as mean±SD, n=3 
 
Assay of FDC (CPX+TNZ and NFX+TNZ) 
The chromatogram peaks were observed at 278 nm for CPX and 318 
nm for TNZ, respectively for CT1 and CT2 brands. For NT1 and NT2 
brands, peaks were observed at 278 nm for NFX and 318 nm for 
TNZ, respectively. The peaks were analyzed for the absorbance at 
their respective λmax to determine the content of the respective 
formulations. The result for assay of brands CT1, CT2, NT1 and NT2 
is compiled and compared in table 2. Thus, the individual drug 
contents of FDC were within the IP limits. 
  
Table 2: Assay outcomes for CPX, NFX and TNZ in individual and combination (FDC) dose 
Brand Drug Label claim (mg) Amount found (mg)±SD % Amount found 
C 1 CPX 500 498.25±0.41 99.65 
250 248.75±0.57 99.50 
C 2 CPX 500 493±0.39 98.6 
250 247.25±0.44 98.9 
N 1 NFX 400 386.56±0.96 99.64 
N 2 NFX 400 390.4±0.61 97.6 
T 1 TNZ 600 499.1±0.47 99.82 
300 298.98±0.25 96.66 
T2 TNZ 600 493.5±0.28 98.7 
300 298.96±0.37 99.42 
CT 1 CPX 500 498.61±0.16 99.72 
TNZ 600 597.48±0.20 99.58 
CT 2 CPX 500 495.38±0.38 99.07 
TNZ 600 596.81±0.82 99.46 
NT 1 NFX 400 396.41±0.74 99.10 
TNZ 600 591.44±0.66 98.57 
NT 2 NFX 400 398.28±0.18 99.57 
TNZ 600 595.68±0.13 99.28 
 
FDC-fixed dose combinations; CPX-ciprofloxacin, NFX-norfloxacin, 
TNZ-tinidazole; C 1 and C 2-marketed tablets of ciprofloxacin 500 
mg/250 mg of 2 brands, respectively, N 1 and N 2-marketed tablets 
of norfloxacin 400 mg of 2 brands, respectively, T 1 and T 2-
marketed tablets of tinidazole 600 mg/300 mg of 2 brands, 
respectively, CT 1 and CT 2 -brands of combination tablets of 
ciprofloxacin 500 mg and tinidazole 600 mg, NT 1 and NT 2-brands 
of combination tablets of norfloxacin 400 mg and tinidazole 600 mg, 
respectively All values are expressed as mean±SD, n=3. 
Dissolution 
The dissolution test was carried as per the dissolution parameters 
specified for 0.01N HCl and phosphate buffer 6.8 [16-18]. Depending 
upon the solubility results and pKa values for CPX (6.09), NFX (6.34) 
and TNZ (4.7), the drug release was more in acidic media i.e. 0.01N 
HCl whereas in phosphate buffer 6.8, the drug release can be lower. 
The results of dissolution test for individual drugs and combination 
dose are presented in fig. 1-5. 
 
 
Fig. 1: Dissolution profile of C1–500/250 mg and C2–500/250 mg tablets in (a) 0.01N HCl and (b) Phosphate buffer 6.8 
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Fig. 2: Dissolution profile of N1 and N2 tablets in (a) 0.01N HCl and (b) Phosphate buffer 6.8 
 
 
Fig. 3: Dissolution profile of T1-500/300 mg and T2-600/300 mg tablets in (a) 0.01N HCl and (b) Phosphate buffer 6.8 
 
 
Fig. 4: Dissolution profile of CT 1 and CT 2 tablets in (a) 0.01N HCl and (b) Phosphate buffer 6.8 
 
 
Fig. 5: Dissolution profile of NT 1 and NT 2 tablets in (a) 0.01N HCl and (b) Phosphate buffer 6.8 
 
The results for dissolution in 0.01N HCl (fig. 1-3) showed that the 
90% of drug release for CPX, NFX and TNZ was achieved in 20 min. 
At the end of 30 min, 99% drug release for individual drugs was 
achieved. For combination dose of CPX+TNZ and NFX+TNZ, the CPX, 
NFX and TNZ release was 90% (Cmax) in 20 min (Tmax) and 99% 
drug released occurred at 30 min (fig. 4-5). 
The results for dissolution in phosphate buffer 6.8 (fig. 1-3) showed 
that, ≤ 50% of drug release for individual CPX and NFX was achieved 
at 60 min and ≤ 60% of drug release for individual TNZ was 
achieved at the end of 60 min. For combination dose of CPX+TNZ 
and NFX+TNZ, ≤ 50% of CPX, NFX were released along with ≤ 60% 
TNZ release at the end of 60 min, respectively. The results for 
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dissolution of combination dose in phosphate buffer 6.8 (fig. 4-5) 
also showed the similar % drug release at 60 min as that of 
individual drugs and no significant difference was observed.  
The results obtained from dissolution test for both, individual drug 
and combination dose illustrated 99% drug release within 30 min in 
0.01N HCl which indicated that stomach as the absorption site. FDC 
in 0.01N HCl and phosphate buffer 6.8 had similar dissolution 
kinetics as that of individual drugs. 
Ex vivo permeation 
The permeation study was performed simultaneously with 
dissolution study so as to build the relation between drug solubility 
and permeation which may give better idea for solubility dependent 
drug absorption. The sample was withdrawn at a single point of 3 h. 
Based upon the pKa values of CPX (6.09) and NFX (6.34), their % 
ionization at pH 7.4 is 80% and 82%, respectively. Also, the log P for 
CPX (0.28) and NFX (0.4) is less than 1 in accordance to their 
hydrophilic nature. From the above consideration for pKa and log P 
for CPX and NFX, the drug permeation could be low in intestinal pH. 
Depending upon the pKa value of TNZ (4.7), % ionization at pH 7.4 is 
about 1% and the log P of the TNZ (1.4) is more than 1 owing to 
more lipophilic nature. From the above consideration for TNZ, the 
permeation of drug could be high in intestinal pH [22]. Based upon 
the log P values, permeability study results indicated that the TNZ 
permeation was higher as compared to that of CPX and NFX in 
individual drugs. The results for combination dose in comparison 
with the individual drugs showed no significant change in the 
permeation rate. The results for permeability study are presented in 
table 3. 
 
Table 3: Outcomes of permeation study for individual drugs and combination products 
Brand Drug Tablet strength (mg) % Drug release±SD % Drug permeated±SD Total % permeation 
C 1 CPX 500 43.36±0.45 21.95±0.38 47.62 
CPX 250 44.80±0.65 22.51±0.29 48.24 
 
C 2 
CPX 500 43.80±0.34 21.97±0.68 50.02 
CPX 250 43.82±0.49 22.39±0.52 51.09 
N 1 NFX 400 47.16±0.75 20.68±0.87 43.85 
N 2 NFX 400 47.18±0.47 20.64±0.62 43.74 
 
T 1 
TNZ 600 47.78±0.37 44.33±0.22 92.77 
TNZ 300 46.52±0.61 42.81±0.41 92.02 
 
T 2 
TNZ 600 47.22±0.68 43.06±0.84 91.19 
TNZ 300 45.84±0.73 41.04±0.69 89.46 
CT 1 CPX 500 44.35±0.17 19.31±0.36 45.34 
TNZ 600 46.35±0.26 41.50±0.11 88.56 
CT 2 CPX 500 44.08±0.61 19.08±0.38 48.28 
TNZ 600 45.66±0.67 41.66±0.31 91.23 
NT 1 NFX 400 44.32±0.51 19.27±0.73 43.47 
TNZ 600 47.30±0.26 42.65±0.61 90.16 
NT 2 NFX 400 43.34±0.13 19.41±0.48 44.78 
TNZ 600 45.71±0.32 42.05±0.78 92.08 
 
CPX-ciprofloxacin, NFX-norfloxacin, TNZ-tinidazole; C 1 and C 2-
marketed tablets of ciprofloxacin 500 mg/250 mg of 2 brands, 
respectively, N 1 and N 2-marketed tablets of norfloxacin 400 mg of 
2 brands, respectively, T 1 and T 2-marketed tablets of tinidazole 
500 mg/300 mg of 2 brands, respectively, CT 1 and CT 2-brands of 
combination tablets of ciprofloxacin 500 mg and tinidazole 600 mg, 
NT 1 and NT 2-brands of combination tablets of norfloxacin 400 mg 
and tinidazole 600 mg, respectively All values are expressed as 
mean±SD, n=3. 
Microbial assay 
The concentration determined as the MIC for CPX, NFX and TNZ was 
found to be 2.5 µg/ml. So, for determining the antimicrobial activity 
of CPX, NFX, TNZ, combination of CPX+TNZ and combination of 
NFX+TNZ, 2.5 µg/ml and 5 µg/ml concentrations were selected and 
added in the respective labeled wells. Plates were incubated at 37 °C. 
After incubation of 24 h, the zone of inhibition was measured in 
millimeter (mm) [23]. 
  
 
Fig. 6: Antimicrobial zones of inhibition of (a) CFX, (b) NFX, (c) TNZ, (d) CFX+TNZ and (e) NFX+TNZ 
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The results for antimicrobial activity showed that zone of 
inhibition for CPX and NFX was more than the combination of 
CPX+TNZ and NFX+TNZ. The zone of inhibition of CPX was more 
than that of NFX. CPX demonstrated better antibacterial activity at 
lower concentration. As CPX and NFX belong to antibacterial 
category, they showed significant activity towards Shigella boydii 
bacteria compared to TNZ, an antiprotozoal. The results for 
combination dose were found to be similar to that of individual 
drugs without any significant change in their antimicrobial 
activities. The zones of inhibition for respective drugs and their 
combinations therein, are represented in fig. 6 and values for the 
same are shown in table 4. Zones of inhibition for individual drugs 
were nearly same as that of their combination dose, CPX+TNZ and 
NFX+TNZ. 
 
Table 4: Antimicrobial zones of inhibition of CPX, NFX and TNZ in individual and combination products 
Brand Drug Tablet strength (mg) Zone of inhibition (mm)±SD 
Concentration (µg/ml) 
2.5 5 
 API (CPX) - 28±0.48 33±0.26 
C 1 CPX 500 26±0.36 31±0.45 
CPX 250 24±0.41 30±0.61 
C 2 CPX 500 27±0.31 31±0.24 
CPX 250 25±0.26 29±0.34 
 API (NFX) - 24±0.74 29±0.29 
N 1 NFX 400 22±0.62 26±0.49 
N 2 NFX 400 21±0.15 26±0.36 
 API (TNZ) - 6±0.36 11±0.18 
T 1 TNZ 600 4±0.25 8±0.37 
TNZ 300 4±0.49 8±0.26 
T 2 TNZ 600 3±0.32 7±0.15 
TNZ 300 3±0.71 8±0.32 
 API (CPX+TNZ) - 28±0.62 31±0.47 
CT 1 CPX+TNZ 500+600 27±0.23 30±0.76 
CT 2 CPX+TNZ 500+600 26±0.65 28±0.15 
 API (NFX+TNZ) - 18±0.51 22±0.41 
NT 1 NFX+TNZ 400+600 16±0.26 20±0.37 
NT 2 NFX+TNZ 400+600 16±0.33 19±0.52 
 
CPX-ciprofloxacin, NFX-norfloxacin, TNZ-tinidazole; C 1 and C 2-
marketed tablets of ciprofloxacin 500 mg/250 mg of 2 brands, 
respectively, N 1 and N 2-marketed tablets of norfloxacin 400 mg of 
2 brands, respectively, T 1 and T 2-marketed tablets of tinidazole 
600 mg/300 mg of 2 brands, respectively, CT 1 and CT 2-brands of 
combination tablets of ciprofloxacin 500 mg and tinidazole 600 mg, 
NT 1 and NT 2-brands of combination tablets of norfloxacin 400 mg 
and tinidazole 600 mg, respectively All values are expressed as 
mean±SD, n=3. 
CONCLUSION 
The rationality of antibacterial and antiprotozoal FDC products 
(ofloxacins and azoles) which are used in the treatment of diarrhea 
was assessed for synergistic effects over the respective individual 
products. Drug assays confirmed the individual drug contents of FDC 
as per Indian Pharmacopoeia. There was no significant difference 
observed in the dissolution kinetics, permeation and antimicrobial 
studies of the combination products in comparison to the individual 
products. Thus, the combination dose can be considered applicable 
in view of cost of manufacturing, packaging and convenience for 
administration. However, there is no direct evidence of therapeutic 
advantage rendered by combination dose of antibacterial and 
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